Details of the Drug
General Information of Drug (ID: DM5K0EI)
Drug Name |
Adamantan-1-yl-piperazin-1-yl-methanone
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
1-(1-adamantylcarbonyl)piperazine; 29869-08-7; adamantanyl piperazinyl ketone; CHEMBL391335; piperazin-1-yl(tricyclo[3.3.1.1~3,7~]dec-1-yl)methanone; adamantan-1-yl-piperazin-1-yl-methanone; AC1Q5KAX; SCHEMBL1150471; CTK4G3954; DTXSID70589438; XAFSAELWLMDLKL-UHFFFAOYSA-N; MolPort-006-345-515; 1-(1-adamantanecarbonyl)piperazine; ALBB-024506; ZINC12343593; STL412114; BDBM50207783; SBB071957; BBL037233; AKOS009097513; MCULE-3925280273; ST072044; EN300-25317; AB00983558-01; piperazine, 1-(tricyclo[3.3.1.1~3,7~]dec-1-ylcarbonyl)-
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 248.36 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.6 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||